OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
October 16, 2022
An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.
Significant improvements have been developed to tackle the challenges in viral vector manufacturing at each stage.
October 15, 2022
How dry powder techniques can overcome limitations in biologics development and delivery to broaden routes of administration and global accessibility.
The authors discuss the differences in mechanism of activation of N-nitrosamides versus N-nitrosamines and the fact that they should not be treated the same.
The author discusses some new applications of TPGS in the pharmaceutical field that should see this versatile excipient retain its place in the drug formulators toolbox.
October 14, 2022
Merck has exercised a $250 million option with Moderna to jointly develop and commercialize cancer vaccine mRNA-4157/V940.
Alexion’s acquisition of LogicBio is designed to accelerate the company’s growth in genomic medicines.
One company reaches beyond traditionally-conceived male contraceptives with Vasalgel, a reversible hydrogel injectable.
October 13, 2022
FDA amended its authorization for the Moderna and Pfizer-BioNTech bivalent booster vaccines to permit their use in children as young as five years old.
Russell Kneipp, who has been Spectrum’s COO since 2018, will assume the roles effective immediately.